Genmab Completes Share Buy-back Program
Ticker: GNMSF · Form: 6-K · Filed: Jun 30, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Jun 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, company-update
TL;DR
Genmab finished its share buyback on June 30, 2025. Details in appendix.
AI Summary
Genmab A/S announced the completion of its share buy-back program on June 30, 2025. The program involved the repurchase of shares, details of which are provided in an appendix to the company announcement.
Why It Matters
Completion of a share buy-back program can signal management's confidence in the company's valuation and potentially lead to an increase in earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine update on a completed share buy-back program and does not introduce new material risks.
Key Players & Entities
- Genmab A/S (company) — Registrant
- June 30, 2025 (date) — Completion date of share buy-back program
FAQ
What was the purpose of the share buy-back program?
The filing does not explicitly state the purpose of the share buy-back program, but it announces its completion.
When was the share buy-back program completed?
The share buy-back program was completed on June 30, 2025.
Where can I find details about the share buy-back program?
Details about the share buy-back program are available in Exhibit 99.1a, titled 'Appendix - Share buyback program'.
Is this filing a 20-F or 40-F report?
This filing is a Form 6-K, and the company indicates it files annual reports under Form 20-F.
What is Genmab A/S's primary business?
Genmab A/S is listed under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 30, 2025 regarding GENMAB A/S (GNMSF).